Results 141 to 150 of about 47,778 (228)

A Design of Experiments‐Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations

open access: yesChirality, Volume 38, Issue 4, April 2026.
A design of experiments–based chiral HPLC method was developed for the enantiomeric separation and quantification of talazoparib in pharmaceutical formulations. Efficient resolution of the enantiomers (RS > 7) was achieved within 12 min. The method was validated and successfully applied to tablet analysis, and its environmental sustainability was ...
Sakine Atila Karaca   +2 more
wiley   +1 more source

Respiratory Virus-Induced PARP1 Alters DC Metabolism and Antiviral Immunity Inducing Pulmonary Immunopathology

open access: yesViruses
Previous studies from our laboratory and others have established the dendritic cell (DC) as a key target of RSV that drives infection-induced pathology. Analysis of RSV-induced transcriptomic changes in RSV-infected DC revealed metabolic gene signatures ...
Mohamed M. Mire   +5 more
doaj   +1 more source

Discovery of Capsazepine as a Novel MCL1 Inhibitor for Overcoming Tamoxifen Resistance in Breast Cancer Therapy

open access: yeseFood, Volume 7, Issue 2, April 2026.
MCL1 in promoting tamoxifen resistance by inhibiting apoptosis. This study demonstrates that the compound CPZ, identified through virtual screening and validated by molecular docking and experiments, directly binds to MCL1. This binding restores apoptosis and inhibits tumor growth, thereby combating resistance to endocrine therapy in breast cancer ...
Shujing Liu   +9 more
wiley   +1 more source

PARP1 condensates differentially partition DNA repair proteins and enhance DNA ligation

open access: yesEMBO Reports
Poly(ADP-ribose) polymerase 1 (PARP1) is one of the first responders to DNA damage and plays crucial roles in recruiting DNA repair proteins through its activity – poly(ADP-ribosyl)ation (PARylation). The enrichment of DNA repair proteins at sites of DNA
Christopher Chin Sang   +10 more
doaj   +1 more source

A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells

open access: yesCell Reports
Summary: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) not only suppress PARP1 catalytic activity but also prolong its association to damaged chromatin.
Petar-Bogomil Kanev   +7 more
doaj   +1 more source

Multiomics Research Strategies in Cancer: A Growing and Innovative Field

open access: yesMedComm, Volume 7, Issue 4, April 2026.
This review highlights multiomics strategies in cancer research, focusing on integration methods from genomics to microbiomics. Using colorectal cancer as a key example, it discusses biomarker discovery, data integration via deep learning, and the roles of single‐cell and spatial omics.
Zhenhua Du   +8 more
wiley   +1 more source

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

open access: yesBiomolecules
The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the ...
Daria O. Koshkina   +5 more
doaj   +1 more source

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi   +5 more
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

open access: yesMedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang   +9 more
wiley   +1 more source

Inflammatory osteolysis: A conspiracy against bone [PDF]

open access: yes, 2017
Abu-Amer   +36 more
core   +2 more sources

Home - About - Disclaimer - Privacy